Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Iparomlimab and Tuvonralimab”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06897046
What this trial is testing

Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)II-IIIB
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 90
Large-scale testing (Phase 3)Not Yet RecruitingNCT07613567
What this trial is testing

A Clinical Study of QL1706 Combined With Chemotherapy as Neoadjuvant Therapy for High-Risk Locally Advanced Cervical Cancer

Who this might be right for
Locally Advanced Cervical Carcinoma
Fujian Cancer Hospital 486
Testing effectiveness (Phase 2)Looking for participantsNCT07801287
What this trial is testing

Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCC

Who this might be right for
HCC - Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital 20
Testing effectiveness (Phase 2)Looking for participantsNCT06829797
What this trial is testing

Randomized Controlled Phase II Trial of Iparomlimab and Tuvonralimab (QL1706) Combined With SOX Chemotherapy Versus Chemotherapy Alone in the Treatment of Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Shandong Provincial Hospital 96
Testing effectiveness (Phase 2)Looking for participantsNCT06908382
What this trial is testing

Neoadjuvant QL1706 Therapy for ESCC

Who this might be right for
Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
Shandong Provincial Hospital 32
Testing effectiveness (Phase 2)Looking for participantsNCT07165847
What this trial is testing

Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)

Who this might be right for
ImmunotherapyGastric Cancer (GC)Radiotherapy+2 more
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 40
Large-scale testing (Phase 3)Looking for participantsNCT07686640
What this trial is testing

Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in pMMR/MSS Locally Advanced Rectal Cancer

Who this might be right for
Local Advanced Rectal CancerRadiotherapyImmunotherapy
Shandong Cancer Hospital and Institute 180
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07200947
What this trial is testing

A Phase II Study of QL1706 and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

Who this might be right for
SMARCA4-Deficient TumorLocally Advanced or Metastatic Non-Small Cell Lung Cancer
Zhijie Wang 28
Testing effectiveness (Phase 2)Looking for participantsNCT07447570
What this trial is testing

Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC

Who this might be right for
Head and Neck CancerRadiotherapyAnti-PD-1/CTLA-4 Antibody
Second Affiliated Hospital, Zhejiang University, School of Medicine 27
Large-scale testing (Phase 3)Not Yet RecruitingNCT07729605
What this trial is testing

FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRC

Who this might be right for
Colorectal Cancer MetastaticMicrosatellite Stable (MSS) Colorectal Cancer (CRC)
Sun Yat-sen University 270
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07413601
What this trial is testing

Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/Third-line Triple Negative Breast Cancer (TNBC)

Who this might be right for
Triple Negative Breast Cancer Metastatic
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 78
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07150377
What this trial is testing

A Phase II Single-Arm Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Lenvatinib and TACE for Advanced Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma (HCC)
The Second Affiliated Hospital of Shandong First Medical University 41
Testing effectiveness (Phase 2)Looking for participantsNCT07601178
What this trial is testing

QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative Breast Cancer

Who this might be right for
TNBC, Triple Negative Breast Cancer
Jiangsu Cancer Institute & Hospital 34
Not applicableLooking for participantsNCT07268131
What this trial is testing

TITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan Criteria

Who this might be right for
Hepatocellular Carcinoma (HCC)
Fudan University 30
Testing effectiveness (Phase 2)Looking for participantsNCT07101744
What this trial is testing

Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial

Who this might be right for
Nasopharyngeal Carcinoma (NPC)First-line Treatment Failure Nasopharyngeal Carcinoma
Sun Yat-sen University 41
Testing effectiveness (Phase 2)Looking for participantsNCT07150247
What this trial is testing

Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer

Who this might be right for
BRAF V600 Colorectal Cancer
Sun Yat-sen University 20
Testing effectiveness (Phase 2)Looking for participantsNCT07392346
What this trial is testing

Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer

Who this might be right for
Gastric Cancer Adenocarcinoma Metastatic
Dai, Guanghai 68
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07035808
What this trial is testing

A Single Arm, Phase II Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of Iparomlimab and Tuvonralima b and Chemotherapy ± Bevacizumab Induction Therapy Followed by Concurrent Chemoradiotherapy in Patients With Advanced Cervical Cancer .

Who this might be right for
Cervical Cancer Stage IVACervical Cancer Metastatic
Zhejiang Cancer Hospital 46
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07446387
What this trial is testing

A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer (CRC)
Jiangsu Cancer Institute & Hospital 70
Testing effectiveness (Phase 2)Looking for participantsNCT07733115
What this trial is testing

QL1706（Iparomlimab/Tuvonralimab) Combined With Gemcitabine and Cisplatin as First-Line Treatment for PD-L1-Positive Biliary Tract Cancer

Who this might be right for
Biliary Tract Cancer (BTC)
Shanghai Zhongshan Hospital 38
Next Page